S. Subbarao, L. Warrener, K. Hoschler, K. Perry, J. Shute, H. Whitaker, Michelle O'Brien, F. Baawuah, P. Moss, H. Parry, S. Ladhani, M. Ramsay, K. Brown, G. Amirthalingam
Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin, 2021
Sera were collected from 185 adults aged ≥ 70 years in London to evaluate the immune response to COVID-19 vaccines. A single dose of Pfizer/BioNtech vaccine resulted in > 94% seropositivity after 3 weeks in naïve individuals using the Roche Spike antibody assay, while two doses produced very high spike antibody levels, significantly higher than convalescent sera from mild-to-moderate PCR-confirmed adult cases. Our findings support the United Kingdom’s approach of prioritising the first dose and delaying the second dose of COVID-19 vaccine.
Cited by 14 publications.
Field of study: Medicine